Developer docs
API playgroundTry for free, no card

Search company profiles

STgen Bio

Full company profile

uuid005dod4

Namestring
STgen Bio
Legal namestring
BTGEN Co., Ltd.
Websiteurl
stgenbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

STgen Bio (now operating as BTGEN following a 2026 rebrand) is a South Korea-based biopharmaceutical Contract Development and Manufacturing Organization (CDMO) headquartered in Songdo, Incheon. Founded in 2015 as a joint venture between Dong-A Socio Holdings and Meiji Seika Pharma under the name DM Bio, the company became a wholly-owned subsidiary of Dong-A Socio Holdings in October 2021 when the Korean parent acquired Meiji's 421 billion KRW stake. The company specializes in mammalian cell culture-based manufacturing of antibody biopharmaceuticals and recombinant proteins, operating a single-site cGMP-certified facility in Songdo that delivers integrated Drug Substance (DS) and Drug Product (DP) services including fully automated pre-filled syringe (PFS) filling, analytical testing, and regulatory support.

The core technology platform is a hybrid mammalian cell culture system combining single-use and multi-use bioreactors up to 2,500L scale, paired with chromatography and ultrafiltration/diafiltration downstream processing. Total production capacity is currently 9,000L, with a 1,100 billion KRW (~$800M USD) expansion to 14,000L planned for Q1 2026 through Q1 2028. The company's commercial pipeline is anchored by biosimilars including DMB-3115 (Stelara biosimilar, FDA BLA approved 2024), DA-3880 (Aranesp biosimilar, supplied to Japan via SKK), and ALT-L9 (Eylea biosimilar, manufactured for Alteogen). Concurrent cGMP approvals from the US FDA, European EMA, and Japan PMDA — with Saudi Arabia SFDA and Health Canada inspections underway — position the company as a globally-credentialed CDMO for biosimilar supply chains.

STgen Bio generates revenue through contract manufacturing and development services billed under multi-year project-based agreements, including upfront, milestone, and commercial supply fee components. Reported revenue reached 58.8 billion KRW (~$42.6M USD) in FY2023, up 46% from FY2022's 40.3 billion KRW (~$29M USD). Customer segments include global pharmaceutical companies (Dong-A ST, Meiji Seika, Intas Pharmaceuticals, Alteogen), Korean bioventure and biotech firms served via CRO/CDO partners (Protium Science), and intra-group Dong-A Socio Holdings affiliates. Go-to-market is enterprise field sales supported by participation in major industry events (INTERPHEX, BIO USA, BIOPLUS-INTERPHEX KOREA) and strategic partnerships with contract development and research organizations.

Short descriptiontext

STgen Bio (BTGEN) is a South Korea-based biopharmaceutical CDMO in Songdo, Incheon, providing integrated Drug Substance and Drug Product manufacturing services for global pharma and biotech clients' biosimilar and antibody pipelines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIncheon, South Korea
HQ citystring
Incheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical contract manufacturing, drug substance manufacturing, pre-filled syringe filling, biosimilar CDMO services, mammalian cell culture
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing (CMO)
TypeOne Time License
Description

Manufacturing biopharmaceuticals (Drug Substance and Drug Product) for pharmaceutical companies under long-term contracts. Revenue is generated through upfront payments, milestone payments, and commercial supply fees.

btgen.co.kr
2CDMO Services
TypeProfessional Services
Description

Full-spectrum contract development and manufacturing services including process development, technology transfer, scale-up engineering, and regulatory support

btgen.co.kr
3Commercial Manufacturing Supply
TypeTransaction Fee
Description

Ongoing supply of commercialized biopharmaceutical products such as DMB-3115, generating recurring revenue from product supply

btgen.co.kr
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Contract pricing based on specific project requirements including manufacturing scale, process complexity, regulatory requirements, and contract duration

btgen.co.kr
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

STgen Bio (BTGEN) is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated one-stop services from Drug Substance (DS) to Drug Product (DP). The company manufactures antibody-based biopharmaceuticals and recombinant proteins using mammalian cell culture with up to 2,500L bioreactors in a hybrid single-use/multi-use platform, performs fully automated pre-filled syringe filling, and provides analytical testing, regulatory support, and cold chain logistics for global pharmaceutical and biosimilar developers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

STgen Bio (BTGEN) is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering fully integrated one-stop CMO/CDMO services. The company's core manufacturing operations include DS Manufacturing (Drug Substance) using mammalian cell culture with up to 2,500L bioreactors in a hybrid single-use/multi-use platform, and DP Manufacturing (Drug Product) featuring fully automated pre-filled syringe filling and secondary packaging with serialization. Supporting services include Analytical Testing (physicochemical, microbial, cell-based testing) and a Quality Management System compliant with global regulatory standards. Key products include DMB-3115 (Stelara biosimilar), DA-3880 (Aranesp biosimilar), and ALT-L9 (Eylea biosimilar). The company serves global markets including Korea, Japan, US, and Europe.

Product and service7 records
1DS Manufacturing (Drug Substance)
CategoryContract Manufacturing Organization (CMO)
Description

Mammalian cell culture manufacturing for antibody-based biopharmaceuticals and recombinant proteins, with bioreactors up to 2,500L and a hybrid single-use/multi-use platform for clinical, PPQ, and commercial supply.

2DP Manufacturing (Drug Product)
CategoryContract Manufacturing Organization (CMO)
Description

Fully automated pre-filled syringe (PFS) filling lines and secondary packaging (blister and carton) with serialization and aggregation capabilities for commercial biologic products.

3Analytical Testing
CategoryContract Development Organization (CDO) Services
Description

Comprehensive physicochemical, microbial, and cell-based testing services including raw materials testing, DS/DP release testing, stability programs, and similarity/comparability testing.

4Quality Management System
CategoryRegulatory Compliance Services
Description

Quality management system in compliance with global regulatory requirements including FDA, EMA, PMDA, and other international standards, covering batch release and regulatory documentation.

5DMB-3115 (Stelara biosimilar)
CategoryBiosimilar Products
Description

Biosimilar of Stelara (ustekinumab) for autoimmune diseases, jointly developed with Dong-A ST and Meiji Seika Pharma, manufactured by STgen Bio for global commercial supply.

6DA-3880 (Aranesp biosimilar)
CategoryBiosimilar Products
Description

Biosimilar of Aranesp (darbepoetin alfa) developed by Dong-A ST for anemia treatment, supplied to Japan through distribution partner SKK.

7ALT-L9 (Eylea biosimilar)
CategoryBiosimilar Products
Description

Biosimilar of Eylea (aflibercept) manufactured and supplied for Alteogen for age-related macular degeneration treatment.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-12-11
Description

MOU for specialized workforce training and education. Partnership focuses on developing customized training programs for platform manufacturing technologies and building degree programs for the bio healthcare industry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Global license-out partnership for DMB-3115 biosimilar. Intas obtained rights to commercialize DMB-3115 in global markets, accelerating STgen Bio's entry into US and European pharmaceutical markets through established distribution networks.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-25
Description

MOU for CDMO business cooperation. Protium Science provides CDO (Contract Development Organization) services as a subsidiary of TiumBio, while STgen Bio provides CMO capabilities. The partnership aims to provide integrated one-stop CDMO services from R&D to production for bioventure companies.

4Dong-A Socio Holdings
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Dong-A Socio Holdings acquired STgen Bio as a subsidiary, unifying the governance structure under single ownership. This enables swift decision-making and focused investment for the company's mid-to-long-term growth strategies. The parent company provides strategic direction and capital support for facility expansion including the 1,100 billion KRW investment.

btgen.co.kr
5Meiji Seika Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Original joint venture partner that established DM Bio (now STgen Bio) with Dong-A Socio Holdings in 2015. Dong-A acquired Meiji's stake in 2021, but partnership continues for DMB-3115 joint development. Meiji brings Japanese market expertise and continues collaboration on biosimilar development.

btgen.co.kr
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Japanese distribution partner for DA-3880 (Darbepoetin alfa biosimilar). SKK handles local sales and distribution in Japan following PMDA approval and market launch in 2019.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean biosimilar developer and manufacturer that also operates CMO services. Directly comparable in biosimilar mAb manufacturing, mammalian cell culture, and global regulatory approvals (FDA/EMA), with a similar customer base of global pharmaceutical partners.

TypeBroad incumbent
Description

Global CDMO with biologics and drug product capabilities including pre-filled syringe filling. Comparable in DP manufacturing and regulatory expertise, but operates across many dosage forms and geographies beyond biologics.

TypeDirect peer
Description

Global biologics CDMO with end-to-end DS and DP services and global regulatory approvals. Closely comparable in integrated CDMO services, pre-filled syringe capabilities, and biosimilar client base, though part of a much larger globally diversified operation.

TypeDirect peer
Description

Global mammalian cell culture CDMO with comparable scale (mid-size bioreactors) and end-to-end biologics services. Closely comparable in mid-tier CDMO positioning, regulatory posture, and biosimilar/biosimilar-adjacent client base.

TypeBroad incumbent
Description

Korea's largest CDMO with 364,000L+ mammalian cell culture capacity. Comparable as a Korean biopharmaceutical CDMO targeting global pharma clients with FDA/EMA cGMP-certified facilities, but far larger and broader in scope (also offering biosimilars development).

6Alteogen
TypeOthers
Description

Korean biosimilar developer and STgen Bio's customer for ALT-L9 (Eylea biosimilar). Comparable as a Korean biosimilar developer with FDA/EMA filings, but operates as a customer rather than a competing CDMO and is a meaningful revenue source for STgen Bio.

TypeBroad incumbent
Description

Global CDMO with mammalian cell culture and drug product capabilities. Comparable in biologics CDMO services and integrated offerings, but part of a larger global conglomerate with much broader capacity.

TypeBroad incumbent
Description

Global leader in biologics CDMO with multi-modality capabilities (mammalian, microbial, cell therapy). Comparable as a large-scale mammalian cell culture CDMO with FDA/EMA approvals, but with significantly greater scale and global multi-site footprint.

TypeEmerging player
Description

Korean mid-size CDMO with mammalian cell culture manufacturing and biosimilar client base. Closely comparable in scale and Korean CDMO positioning, also serving biosimilar developers with similar drug substance and drug product offerings.

TypeRegional player
Description

Korean biopharmaceutical manufacturer with both vaccines and biologics capabilities. Comparable as a Korean CDMO adjacent to the Dong-A Socio Group ecosystem, but more focused on vaccines and tends to operate in rather than license out.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STgen Bio

Biopharmaceutical Contract Manufacturing (CDMO)stgenbio.com

STgen Bio (BTGEN) is a South Korea-based biopharmaceutical CDMO in Songdo, Incheon, providing integrated Drug Substance and Drug Product manufacturing services for global pharma and biotech clients' biosimilar and antibody pipelines.

What STgen Bio does

STgen Bio (now operating as BTGEN following a 2026 rebrand) is a South Korea-based biopharmaceutical Contract Development and Manufacturing Organization (CDMO) headquartered in Songdo, Incheon. Founded in 2015 as a joint venture between Dong-A Socio Holdings and Meiji Seika Pharma under the name DM Bio, the company became a wholly-owned subsidiary of Dong-A Socio Holdings in October 2021 when the Korean parent acquired Meiji's 421 billion KRW stake. The company specializes in mammalian cell culture-based manufacturing of antibody biopharmaceuticals and recombinant proteins, operating a single-site cGMP-certified facility in Songdo that delivers integrated Drug Substance (DS) and Drug Product (DP) services including fully automated pre-filled syringe (PFS) filling, analytical testing, and regulatory support.

The core technology platform is a hybrid mammalian cell culture system combining single-use and multi-use bioreactors up to 2,500L scale, paired with chromatography and ultrafiltration/diafiltration downstream processing. Total production capacity is currently 9,000L, with a 1,100 billion KRW (~$800M USD) expansion to 14,000L planned for Q1 2026 through Q1 2028. The company's commercial pipeline is anchored by biosimilars including DMB-3115 (Stelara biosimilar, FDA BLA approved 2024), DA-3880 (Aranesp biosimilar, supplied to Japan via SKK), and ALT-L9 (Eylea biosimilar, manufactured for Alteogen). Concurrent cGMP approvals from the US FDA, European EMA, and Japan PMDA — with Saudi Arabia SFDA and Health Canada inspections underway — position the company as a globally-credentialed CDMO for biosimilar supply chains.

STgen Bio generates revenue through contract manufacturing and development services billed under multi-year project-based agreements, including upfront, milestone, and commercial supply fee components. Reported revenue reached 58.8 billion KRW (~$42.6M USD) in FY2023, up 46% from FY2022's 40.3 billion KRW (~$29M USD). Customer segments include global pharmaceutical companies (Dong-A ST, Meiji Seika, Intas Pharmaceuticals, Alteogen), Korean bioventure and biotech firms served via CRO/CDO partners (Protium Science), and intra-group Dong-A Socio Holdings affiliates. Go-to-market is enterprise field sales supported by participation in major industry events (INTERPHEX, BIO USA, BIOPLUS-INTERPHEX KOREA) and strategic partnerships with contract development and research organizations.

STgen Bio firmographics

Firmographics
Name
STgen Bio
Legal name
BTGEN Co., Ltd.
Website
https://stgenbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
STgen Bio (BTGEN) is a South Korea-based biopharmaceutical CDMO in Songdo, Incheon, providing integrated Drug Substance and Drug Product manufacturing services for global pharma and biotech clients' biosimilar and antibody pipelines.
Ownership category
akta.pro rank

STgen Bio industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biopharmaceutical contract manufacturing
  • Drug substance manufacturing
  • Pre-filled syringe filling
  • Biosimilar CDMO services
  • Mammalian cell culture

Where STgen Bio is headquartered

Location

Headquarters

HQ city
Incheon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

STgen Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing (CMO): Manufacturing biopharmaceuticals (Drug Substance and Drug Product) for pharmaceutical companies under long-term contracts. Revenue is generated through upfront payments, milestone payments, and commercial supply fees.
  2. CDMO Services: Full-spectrum contract development and manufacturing services including process development, technology transfer, scale-up engineering, and regulatory support
  3. Commercial Manufacturing Supply: Ongoing supply of commercialized biopharmaceutical products such as DMB-3115, generating recurring revenue from product supply

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

STgen Bio product offering

Product offering

Core offering

STgen Bio (BTGEN) is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated one-stop services from Drug Substance (DS) to Drug Product (DP). The company manufactures antibody-based biopharmaceuticals and recombinant proteins using mammalian cell culture with up to 2,500L bioreactors in a hybrid single-use/multi-use platform, performs fully automated pre-filled syringe filling, and provides analytical testing, regulatory support, and cold chain logistics for global pharmaceutical and biosimilar developers.

Product overview

STgen Bio (BTGEN) is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering fully integrated one-stop CMO/CDMO services. The company's core manufacturing operations include DS Manufacturing (Drug Substance) using mammalian cell culture with up to 2,500L bioreactors in a hybrid single-use/multi-use platform, and DP Manufacturing (Drug Product) featuring fully automated pre-filled syringe filling and secondary packaging with serialization. Supporting services include Analytical Testing (physicochemical, microbial, cell-based testing) and a Quality Management System compliant with global regulatory standards. Key products include DMB-3115 (Stelara biosimilar), DA-3880 (Aranesp biosimilar), and ALT-L9 (Eylea biosimilar). The company serves global markets including Korea, Japan, US, and Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • DS Manufacturing (Drug Substance) Mammalian cell culture manufacturing for antibody-based biopharmaceuticals and recombinant proteins, with bioreactors up to 2,500L and a hybrid single-use/multi-use platform for clinical, PPQ, and commercial supply.
  • DP Manufacturing (Drug Product) Fully automated pre-filled syringe (PFS) filling lines and secondary packaging (blister and carton) with serialization and aggregation capabilities for commercial biologic products.
  • Analytical Testing Comprehensive physicochemical, microbial, and cell-based testing services including raw materials testing, DS/DP release testing, stability programs, and similarity/comparability testing.
  • Quality Management System Quality management system in compliance with global regulatory requirements including FDA, EMA, PMDA, and other international standards, covering batch release and regulatory documentation.
  • DMB-3115 (Stelara biosimilar) Biosimilar of Stelara (ustekinumab) for autoimmune diseases, jointly developed with Dong-A ST and Meiji Seika Pharma, manufactured by STgen Bio for global commercial supply.
  • DA-3880 (Aranesp biosimilar) Biosimilar of Aranesp (darbepoetin alfa) developed by Dong-A ST for anemia treatment, supplied to Japan through distribution partner SKK.
  • ALT-L9 (Eylea biosimilar) Biosimilar of Eylea (aflibercept) manufactured and supplied for Alteogen for age-related macular degeneration treatment.

Companies that use STgen Bio

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

STgen Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

STgen Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Yonsei University K-NIBRTminorStrategic or Co-development Partner · 11 December 2023MOU for specialized workforce training and education. Partnership focuses on developing customized training programs for platform manufacturing technologies and building degree programs for the bio healthcare industry.
  • Intas PharmaceuticalscoreStrategic or Co-development Partner · 1 July 2022Global license-out partnership for DMB-3115 biosimilar. Intas obtained rights to commercialize DMB-3115 in global markets, accelerating STgen Bio's entry into US and European pharmaceutical markets through established distribution networks.
  • Protium SciencecoreStrategic or Co-development Partner · 25 November 2021MOU for CDMO business cooperation. Protium Science provides CDO (Contract Development Organization) services as a subsidiary of TiumBio, while STgen Bio provides CMO capabilities. The partnership aims to provide integrated one-stop CDMO services from R&D to production for bioventure companies.
  • Dong-A Socio HoldingscoreStrategic or Co-development Partner · 1 October 2021Dong-A Socio Holdings acquired STgen Bio as a subsidiary, unifying the governance structure under single ownership. This enables swift decision-making and focused investment for the company's mid-to-long-term growth strategies. The parent company provides strategic direction and capital support for facility expansion including the 1,100 billion KRW investment.
  • Meiji Seika PharmacoreStrategic or Co-development PartnerOriginal joint venture partner that established DM Bio (now STgen Bio) with Dong-A Socio Holdings in 2015. Dong-A acquired Meiji's stake in 2021, but partnership continues for DMB-3115 joint development. Meiji brings Japanese market expertise and continues collaboration on biosimilar development.
  • SKK (Sankyo Kagaku)minorChannel Partner/ Reseller/ DistributorJapanese distribution partner for DA-3880 (Darbepoetin alfa biosimilar). SKK handles local sales and distribution in Japan following PMDA approval and market launch in 2019.

Scale indicators8 records

Recent moves10 records

Expansion highlights5 records

STgen Bio competitors and assessment

Company assessment

Direct peers

  • Celltrion: Korean biosimilar developer and manufacturer that also operates CMO services. Directly comparable in biosimilar mAb manufacturing, mammalian cell culture, and global regulatory approvals (FDA/EMA), with a similar customer base of global pharmaceutical partners.
  • WuXi Biologics: Global biologics CDMO with end-to-end DS and DP services and global regulatory approvals. Closely comparable in integrated CDMO services, pre-filled syringe capabilities, and biosimilar client base, though part of a much larger globally diversified operation.
  • AGC Biologics: Global mammalian cell culture CDMO with comparable scale (mid-size bioreactors) and end-to-end biologics services. Closely comparable in mid-tier CDMO positioning, regulatory posture, and biosimilar/biosimilar-adjacent client base.

Broad incumbents

  • Catalent: Global CDMO with biologics and drug product capabilities including pre-filled syringe filling. Comparable in DP manufacturing and regulatory expertise, but operates across many dosage forms and geographies beyond biologics.
  • Samsung Biologics: Korea's largest CDMO with 364,000L+ mammalian cell culture capacity. Comparable as a Korean biopharmaceutical CDMO targeting global pharma clients with FDA/EMA cGMP-certified facilities, but far larger and broader in scope (also offering biosimilars development).
  • Fujifilm Diosynth Biotechnologies: Global CDMO with mammalian cell culture and drug product capabilities. Comparable in biologics CDMO services and integrated offerings, but part of a larger global conglomerate with much broader capacity.
  • Lonza Group: Global leader in biologics CDMO with multi-modality capabilities (mammalian, microbial, cell therapy). Comparable as a large-scale mammalian cell culture CDMO with FDA/EMA approvals, but with significantly greater scale and global multi-site footprint.

Others

  • Alteogen: Korean biosimilar developer and STgen Bio's customer for ALT-L9 (Eylea biosimilar). Comparable as a Korean biosimilar developer with FDA/EMA filings, but operates as a customer rather than a competing CDMO and is a meaningful revenue source for STgen Bio.

Emerging players

  • Prestige Biologics: Korean mid-size CDMO with mammalian cell culture manufacturing and biosimilar client base. Closely comparable in scale and Korean CDMO positioning, also serving biosimilar developers with similar drug substance and drug product offerings.

Regional players

  • SK Bioscience: Korean biopharmaceutical manufacturer with both vaccines and biologics capabilities. Comparable as a Korean CDMO adjacent to the Dong-A Socio Group ecosystem, but more focused on vaccines and tends to operate in rather than license out.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

STgen Bio social profiles

Digital presence

STgen Bio compliance and trust

Trust signal

Compliance7 records

STgen Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STgen Bio leadership team

Management profile

Number of profiles

Profiles1 record

STgen Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STgen Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STgen Bio

What does STgen Bio do?

STgen Bio (BTGEN) is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated one-stop services from Drug Substance (DS) to Drug Product (DP). The company manufactures antibody-based biopharmaceuticals and recombinant proteins using mammalian cell culture with up to 2,500L bioreactors in a hybrid single-use/multi-use platform, performs fully automated pre-filled syringe filling, and provides analytical testing, regulatory support, and cold chain logistics for global pharmaceutical and biosimilar developers.

Is STgen Bio a public or private company?

STgen Bio is a private company. It is classified as corporate owned and is currently operating.

When was STgen Bio founded?

STgen Bio was founded in 2015. It employs 101 to 250 people.

Where is STgen Bio based?

STgen Bio is headquartered in Incheon, South Korea, in the Asia region.

How does STgen Bio make money?

Three revenue lines are on record. Contract Manufacturing (CMO) is the primary driver. The others are CDMO Services and commercial Manufacturing Supply.

Who are STgen Bio's main competitors?

Direct peers on record are Celltrion, WuXi Biologics and AGC Biologics. Broad incumbents are Catalent, Samsung Biologics, Fujifilm Diosynth Biotechnologies and Lonza Group. Alteogen is listed as an others. Prestige Biologics is listed as an emerging player. SK Bioscience is listed as a regional player.

Does STgen Bio have an API?

No public API is recorded for STgen Bio.

What industry is STgen Bio in?

STgen Bio's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals